Tepotinib: Management of Adverse Events in Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer.

ABSTRACT:

Background

Tepotinib, a highly selective, oral, once-daily MET inhibitor, has been approved for treatment of metastatic MET exon 14 skipping non-small cell lung cancer.

Objectives

This article provides nurse-specific recommendations for identification and management of tepotinib adverse events (AEs).

Methods

Guidance on monitoring and proactive/reactive AE management was developed based on published literature and real-world nursing experience. Case studies of VISION trial participants were summarized to illustrate key principles.

Findings

Tepotinib AEs are generally mild to moderate and manageable, and can include peripheral edema, hypoalbuminemia, nausea, diarrhea, and creatinine increase. Alongside supportive care, tepotinib interruption and dose reduction i

SUBMITTER: Ahn L 

PROVIDER: S-EPMC10034867 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature